Naltrexone: A Cornerstone in Medication-Assisted Treatment for Addiction
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $7.19 | $215.81 (0%) | 🛒 Add to cart |
| 60 | $6.81 | $431.61 $408.42 (5%) | 🛒 Add to cart |
| 90 | $6.67
Best per pill | $647.42 $600.02 (7%) | 🛒 Add to cart |
Synonyms | |||
Naltrexone is a potent opioid antagonist medication primarily indicated for the management of alcohol use disorder and opioid use disorder. It functions by competitively binding to opioid receptors in the brain, effectively blocking the euphoric and sedative effects of opioids and reducing the rewarding effects of alcohol. This pharmacological action supports long-term recovery by helping to diminish cravings and prevent relapse, making it an integral component of a comprehensive treatment plan that includes counseling and psychosocial support. Its availability in both oral and extended-release injectable formulations provides flexibility to meet diverse patient needs and adherence challenges.
Features
- Pharmacological Class: Pure opioid antagonist.
- Available Formulations: Oral tablet (50 mg standard) and extended-release intramuscular injectable suspension (380 mg/vial).
- Mechanism of Action: Competitively binds to mu-opioid receptors, blocking the effects of exogenous opioids.
- Bioavailability: Oral bioavailability ranges from 5% to 40%; the injectable formulation provides sustained release over approximately 4 weeks.
- Metabolism: Primarily hepatic, via dihydrodiol dehydrogenase.
- Elimination Half-life: Oral: approximately 4 hours; Injectable: 5-10 days (release phase dependent).
- Regulatory Status: FDA-approved for alcohol dependence and opioid dependence.
Benefits
- Reduces Cravings: Effectively diminishes the intense desire or urge to consume alcohol or opioids, a significant driver of relapse.
- Blocks Opioid Effects: Prevents the euphoric high associated with opioid use, removing the primary reinforcement for continued misuse.
- Supports Long-Term Abstinence: By mitigating the pharmacological rewards of substance use, it provides a stable foundation for patients to engage in and benefit from behavioral therapies.
- Non-Addictive and Non-Narcotic: As an antagonist, it has no abuse potential or risk of developing physical dependence itself.
- Flexible Dosing Options: The availability of a monthly injectable (Vivitrol®) eliminates the need for daily pill-taking, improving adherence and reducing the risk of missed doses.
- Facilitates Neuroadaptive Recovery: Helps restore balance to brain circuits altered by chronic substance use over time.
Common use
Naltrexone is a cornerstone of Medication-Assisted Treatment (MAT) for substance use disorders. Its primary and FDA-approved uses are for the maintenance of abstinence in patients with alcohol dependence and for the prevention of relapse in patients with opioid dependence who have undergone complete detoxification. It is critically important that a patient is entirely free from opioids before initiating naltrexone therapy to avoid precipitating acute and severe withdrawal. Beyond its approved indications, naltrexone is sometimes used off-label at low doses (Low-Dose Naltrexone or LDN) for conditions involving immune dysregulation and chronic inflammation, such as fibromyalgia, Crohn’s disease, and multiple sclerosis, though robust clinical evidence for these uses is still evolving.
Dosage and direction
For Alcohol Dependence:
- Oral (Tablet): The recommended dose is 50 mg once daily. Some protocols may utilize a reduced schedule of 100 mg every other day or 150 mg every third day to improve adherence, though daily dosing is standard.
- Injectable (Vivitrol®): 380 mg delivered via intramuscular gluteal injection once every 4 weeks (monthly). The injection must be administered by a healthcare professional.
For Opioid Dependence:
- Initiation: Treatment should NOT be started until the patient is completely opioid-free. A naloxone challenge test or a 7-10 day opioid-free period (longer for long-acting opioids like methadone) is mandatory to avoid precipitated withdrawal.
- Oral (Tablet): Begin with a test dose of 25 mg. If no signs of withdrawal appear, the full maintenance dose of 50 mg once daily can be initiated.
- Injectable (Vivitrol®): 380 mg intramuscular gluteal injection once every 4 weeks. The first injection is typically administered after the patient is stabilized on the oral formulation and confirms tolerance.
Administration Notes:
- Oral tablets can be taken with or without food.
- The injectable suspension requires thorough suspension prior to administration.
Precautions
- Opioid Abstinence Verification: The most critical precaution is ensuring the patient is opioid-free. Initiating naltrexone in an opioid-dependent individual will precipitate acute withdrawal, which can be severe.
- Hepatotoxicity: Although rare at recommended doses, dose-related hepatocellular injury has been reported. Liver function tests should be obtained at baseline and monitored during therapy, especially in patients with pre-existing liver disease or acute hepatitis.
- Depression and Suicidality: As with many treatments for addiction, patients should be monitored for the emergence or worsening of depression, suicidal ideation, or suicidal behavior.
- Opioid Overdose Risk: Patients may have a reduced tolerance to opioids after a period of naltrexone-induced abstinence. Attempting to overcome the blockade by taking large amounts of opioids can lead to fatal respiratory depression, coma, or death.
- Renal Impairment: Use with caution in patients with moderate to severe renal impairment.
- Pneumonia: There have been reports of eosinophilic pneumonia associated with the injectable formulation.
Contraindications
- Current physical dependence on opioids or acute opioid withdrawal.
- Failure to pass a naloxone challenge test or recent use of opioids.
- Acute hepatitis or liver failure.
- Known hypersensitivity to naltrexone or any component of the formulation (e.g., polylactide-co-glycolide or carboxymethylcellulose in the injectable).
- The injectable formulation is contraindicated in patients with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection.
Possible side effect
Common side effects are often transient and may include:
- Nausea (most common with oral formulation)
- Headache
- Dizziness
- Insomnia
- Anxiety
- Fatigue
- Abdominal pain/cramps
- Joint and muscle pain
Less common but more serious side effects require medical attention:
- Signs of hepatotoxicity (e.g., dark urine, jaundice, right upper quadrant pain)
- Severe injection site reactions (induration, cellulitis, hematoma, necrosis)
- Depression or suicidal thoughts
- Eosinophilic pneumonia (with injectable)
- Allergic pneumonitis (with injectable)
Drug interaction
- Opioid Analgesics: Naltrexone will block the therapeutic effects of opioid pain medications, including those used for surgical analgesia, trauma, or severe acute pain. Alternative, non-opioid pain management strategies must be planned.
- Opioid-Containing Medications: Will block the effects of opioid agonists in medications like cough suppressants (e.g., codeine, hydrocodone) and antidiarrheals (e.g., diphenoxylate/atropine).
- Thioridazine: Naltrexone may increase the drowsiness caused by thioridazine.
- Yohimbine: The combination may lead to increased anxiety and nervousness.
- Hepatotoxic Drugs: Concomitant use with other drugs known to cause hepatotoxicity (e.g., certain antifungals, anticonvulsants) may increase the risk of liver injury.
Missed dose
- Oral Formulation: If a daily dose is missed, the patient should take it as soon as they remember. If it is close to the time of the next dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should NOT double the next dose to make up for a missed one.
- Injectable Formulation: The monthly injection schedule should be maintained. If an appointment is missed, the healthcare provider should be contacted immediately to reschedule the injection. The protection from the previous injection wanes after 4-5 weeks, increasing relapse risk.
Overdose
There is no evidence of a specific toxic syndrome from naltrexone overdose. Doses significantly higher than those recommended have been administered without serious issues. However, massive overdose could theoretically cause liver injury. Management is supportive and symptomatic. It is crucial to remember that in the event of a trauma or need for surgery, the opioid blockade will persist. Healthcare providers must be informed of naltrexone use so that alternative, effective pain management can be provided.
Storage
- Oral Tablets: Store at room temperature (20°-25°C or 68°-77°F) in a tight, light-resistant container. Keep out of reach of children and pets.
- Injectable Suspension (Vivitrol®): Refrigerate at 2°-8°C (36°-46°F) in the original carton to protect from light. Do not freeze. The kit must be brought to room temperature for at least 45 minutes prior to mixing and administration. Once mixed, the suspension must be administered within 24 hours.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The author and publisher are not responsible for any errors or omissions or for any outcomes related to the use of this information.
Reviews
- “As an addiction psychiatrist, naltrexone is a first-line tool in my arsenal. The injectable formulation, in particular, has been a game-changer for patients with adherence challenges, providing a consistent ‘safety net’ that allows them to focus on therapy.” – Dr. A., MD
- “After multiple relapses on alcohol, starting monthly Vivitrol shots was the stability I needed. The constant cravings subsided significantly, giving me the mental space to actually work my program. It’s not a magic cure, but it’s a powerful aid.” – Patient J., 3 years in recovery.
- “The evidence base for naltrexone in opioid use disorder is strong. It offers a non-controlled, non-addicting option for patients who may not be candidates for agonist therapy like buprenorphine. The key is proper patient selection and ensuring full detoxification first.” – Clinical Pharmacist, MAT Clinic.
- “I experienced some nausea and sleep issues during the first week on the oral tablets, but my doctor warned me it might happen. They subsided, and the benefit of not constantly thinking about drinking has been worth it.” – Patient M.